Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y6SQ
|
|||
| Former ID |
DNC000384
|
|||
| Drug Name |
Camostat
|
|||
| Synonyms |
Camostat; 59721-28-7; camostate; Camostat [INN]; Camostatum [INN-Latin]; UNII-0FD207WKDU; CCRIS 7219; 4-(2-(2-(Dimethylamino)-2-oxoethoxy)-2-oxoethyl)phenyl 4-guanidinobenzoate; 0FD207WKDU; C20H22N4O5; Camostat (INN); Foipan; FOY 305; FOY-305; Dimethylcarbamoylmethyl 4-(4-guqnidinobenzoyloxy)phenylacetat; foypan; Camostatum; CHEMBL85164; camostate-mesilate; [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(diaminomethylideneamino)benzoate; p-Guanidinobenzoic acid, ester with (p-hydroxyphenyl)acetic acid, ester with N
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cystic fibrosis [ICD-11: CA25; ICD-10: E84, E84.9; ICD-9: 277] | Phase 2 | [1], [2], [3], [4] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H22N4O5
|
|||
| Canonical SMILES |
CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N
|
|||
| InChI |
1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23)
|
|||
| InChIKey |
XASIMHXSUQUHLV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 59721-28-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5007223, 14805652, 29143617, 29221698, 50064960, 50112779, 51042575, 51091916, 57321361, 103724215, 103940268, 104300875, 125679011, 126685953, 129661767, 134339826, 135027552, 135727667, 137249290, 142058243, 144115777, 164153587, 164784054, 164814510, 174006694, 178103048, 179150742, 198975915, 223675465, 226496037, 241102503, 249582621, 252346989
|
|||
| ChEBI ID |
CHEBI:135632
|
|||
| SuperDrug ATC ID |
B02AB04
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serine protease unspecific (SP) | Target Info | Inhibitor | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6432). | |||
| REF 2 | Effect of a specific serine protease inhibitor on the rat pancreas: systemic administration of camostate and exocrine pancreatic secretion. Digestion. 1984;30(3):171-8. | |||
| REF 3 | Effects of the serine protease inhibitors FOY and FOY 305 on phospholipase A1 (EC 3.1.1.32) activity in rat - liver lysosomes. Pharmacol Res Commun. 1983 May;15(5):451-9. | |||
| REF 4 | Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats. J Gastroenterol Hepatol. 2005 Jun;20(6):895-9. | |||
| REF 5 | Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens. 2009 Jan;27(1):181-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.